Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 54 citing articles:

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes
Gerasimos Filippatos, George L. Bakris, Bertram Pitt, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 2, pp. 142-152
Open Access | Times Cited: 113
Acute antiarrhythmic effects of SGLT2 inhibitors–dapagliflozin lowers the excitability of atrial cardiomyocytes
A Paasche, Felix Wiedmann, Manuel Kraft, et al.
Basic Research in Cardiology (2024) Vol. 119, Iss. 1, pp. 93-112
Open Access | Times Cited: 21
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i—Arrhythmias and Sudden Cardiac Death)
Jia Liao, Ramin Ebrahimi, Zhiyu Ling, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 21
In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study
Arturo Cesaro, Felice Gragnano, Pasquale Paolisso, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 62
SGLT2 Inhibitors and Their Antiarrhythmic Properties
Ewald Kolesnik, Douglas S. Scherr, Ursula Rohrer, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1678-1678
Open Access | Times Cited: 42
Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors on Outcomes After Catheter Ablation for Atrial Fibrillation
Hideyuki Kishima, Takanao Mine, Eiji Fukuhara, et al.
JACC. Clinical electrophysiology (2022) Vol. 8, Iss. 11, pp. 1393-1404
Open Access | Times Cited: 42
The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review
Panagiotis Stachteas, Athina Nasoufidou, Efstratios Karagiannidis, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 18, pp. 5408-5408
Open Access | Times Cited: 9
Cardiovascular outcomes with SGLT-2 inhibitors in individuals with diabetes and co-existing atrial fibrillation: A systematic review and meta-analysis
Muhammad Zain Ameer, Muhammad Aemaz Ur Rehman, Zunaira Amjad, et al.
International Journal of Cardiology (2025), pp. 133083-133083
Closed Access | Times Cited: 1
SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
Benedetta Maria Bonora, Emanuel Raschi, Angelo Avogaro, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 50
Glycemic control and atrial fibrillation: an intricate relationship, yet under investigation
Αndreas S. Papazoglou, Αναστάσιος Κάρτας, Dimitrios V. Moysidis, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 34
Mechanisms Underlying Antiarrhythmic Properties of Cardioprotective Agents Impacting Inflammation and Oxidative Stress
Katarína Andelová, Barbara Szeiffová Bačová, Matúš Sýkora, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1416-1416
Open Access | Times Cited: 33
Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives
Alfredo Mauriello, Antonia Ascrizzi, Anna Selvaggia Roma, et al.
Antioxidants (2024) Vol. 13, Iss. 7, pp. 806-806
Open Access | Times Cited: 6
The potential anti-arrhythmic effect of SGLT2 inhibitors
Hong-Yi Duan, Héctor Barajas-Martínez, Charles Antzelevitch, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 6
The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study
Yi‐Hsin Chan, Tze‐Fan Chao, Shao‐Wei Chen, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 28
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes
Min Zhuo, Elvira D’Andrea, Julie M. Paik, et al.
JAMA Network Open (2022) Vol. 5, Iss. 10, pp. e2235995-e2235995
Open Access | Times Cited: 25
Incident heart failure and myocardial infarction in sodium‐glucose cotransporter‐2 vs. dipeptidyl peptidase‐4 inhibitor users
Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 2, pp. 1388-1399
Open Access | Times Cited: 24
Sodium‐Glucose Cotransporter‐2 Inhibitor Prevents Stroke in Patients With Diabetes and Atrial Fibrillation
Sheng‐Nan Chang, Jien‐Jiun Chen, Pang‐Shuo Huang, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 10
Open Access | Times Cited: 16
Antidiabetic agents and risk of atrial fibrillation/flutter: A comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists
André Scheen
Diabetes & Metabolism (2022) Vol. 48, Iss. 6, pp. 101390-101390
Closed Access | Times Cited: 22
Benefits of SGLT2 inhibitors in arrhythmias
Jinghan Gao, Genlong Xue, Ge Zhan, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 21
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
Antonis A. Manolis, Theodora A. Manolis, Helen Melita, et al.
Trends in Cardiovascular Medicine (2022) Vol. 33, Iss. 7, pp. 418-428
Closed Access | Times Cited: 20
Sodium–Glucose Cotransporter 2 Inhibitor Treatment and Risk of Atrial Fibrillation: Scandinavian Cohort Study
Arvid Engström, Viktor Wintzell, Mads Melbye, et al.
Diabetes Care (2022) Vol. 46, Iss. 2, pp. 351-360
Open Access | Times Cited: 20
Atrial Fibrillation and Diabetes Mellitus: Dangerous Liaisons or Innocent Bystanders?
Ana Lorenzo-Almorós, J. Casado, Luis Antonio Álvarez-Sala Walther, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2868-2868
Open Access | Times Cited: 12
Impact of SGLT2 Inhibitors on Atrial Fibrillation Recurrence after Catheter Ablation in Type 2 Diabetes Mellitus: A Meta-Analysis of Reconstructed Kaplan–Meier Curves with Trial Sequential Analysis
Youssef Soliman, Mohamed Abuelazm, Basma Ehab Amer, et al.
American Journal of Cardiovascular Drugs (2024) Vol. 24, Iss. 5, pp. 629-640
Open Access | Times Cited: 4
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
Yongin Cho, Sung‐Hee Shin, Min-Ae Park, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0314454-e0314454
Open Access
Mitochondrial Dysfunction in Atrial Fibrillation—Mechanisms and Pharmacological Interventions
Paweł Muszyński, Tomasz A. Bonda
Journal of Clinical Medicine (2021) Vol. 10, Iss. 11, pp. 2385-2385
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top